All In MedTech

FDA Clearance Tracker · P130013-S059

WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device with Delivery System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 31, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 31, 2023

Approved

Time to decision

41 days

Received Sep 20, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P130013-S059
Device name
WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device with Delivery System
Applicant location
Maple Grove, MN
Received
Sep 20, 2023
Decided
Oct 31, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P130013

Device type

Device class
Class III

Every decision under product code NGV

FDA's approval statement

As written in FDA's record.

Approval of the protocol (amended via email on October 26, 2023) for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P130013/S057.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.